Baird downgraded Tenet Healthcare (THC) to Neutral from Outperform with a price target of $137, down from $153. The firm sees minimal incremental buyers of stocks in the managed care and healthcare facilities group until the policy overhang clears. Baird does not not expect guidance raises as it believes companies will maintain 2025 “conservatism and cushion” given potential Part D and macro headwinds that may evolve later this year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Apple, Starbucks upgraded: Wall Street’s top analyst calls
- Tenet initiated with Buy, named best idea at Guggenheim
- Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts
- Wingstop initiated, CarMax upgraded: Wall Street’s top analyst calls
- Tenet Healthcare’s Strategic Transformation and Growth Potential Justifies Buy Rating